잠시만 기다려 주세요. 로딩중입니다.

Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7

BMB Reports 2021년 54권 1호 p.21 ~ 30
소속 상세정보

Abstract


Clinical trials have demonstrated that an increased number of effector cells, especially tumor-specific T cells, is positively linked with patients’ prognosis. Although the discovery of checkpoint inhibitors (CPIs) has led to encouraging progress in cancer immunotherapy, the lack of either T cells or targets for CPIs is a limitation for patients with poor prognosis. Since interleukin (IL)-2 and IL-7 are cytokines that target many aspects of T-cell responses, they have been used to treat cancers. In this review, we focus on the basic biology of how these cytokines regulate T-cell response and on the clinical trials using the cytokines against cancer. Further, we introduce several recent studies that aim to improve cytokines’ biological activities and find the strategy for combination with other therapeutics.

키워드

Cancer immunotherapy; Cytokine; IL-2; IL-7; T cells

원문 및 링크아웃 정보

등재저널 정보